[EN] NOVEL 14 AND 15 MEMBERED RING COMPOUNDS<br/>[FR] NOUVEAUX COMPOSES CYCLIQUES DE 14 ET DE 15 CHAINONS
申请人:GLAXO GROUP LTD
公开号:WO2004101588A1
公开(公告)日:2004-11-25
The present invention relates to 14- or 15-membered macrolides substituted at the 4' position of formula (I) and pharmaceutically acceptable derivatives thereof, to processes for their preparation and their use in therapy or prophylaxis of systemic or topical microbial infections in a human or animal body.
[EN] ESTER LINKED MACROLIDES USEFUL FOR THE TREATMENT OF MICROBIAL INFECTIONS<br/>[FR] MACROLIDES A LIAISON ESTER UTILES POUR LE TRAITEMENT D'INFECTION MICROBIENNES
申请人:PLIVA ISTRAZIVACKI INST D O O
公开号:WO2005108412A1
公开(公告)日:2005-11-17
The present invention relates to 14- or 15-membered macrolides substituted at the 4” position of formula (I) and pharmaceutically acceptable derivatives thereof, to processes for their preparation and their use in therapy or prophylaxis of systemic or topical microbial infoections in a human or animal body.
[EN] NOVEL 14 AND 15 MEMBERED-RING COMPOUNDS<br/>[FR] NOUVEAU COMPOSES A CYCLE RAMIFIE EN 14 ET 15.
申请人:GLAXO GROUP LTD
公开号:WO2004101586A1
公开(公告)日:2004-11-25
The present invention relates to 14- or 15-membered macrolides substituted at the 4' position of formula (I) and pharmaceutically acceptable derivatives thereof, to processes for their preparation and their use in therapy or prophylaxis of systemic or topical microbial infections in a human or animal body.
[EN] MACROLIDES SUBSTITUTED AT THE 3-POSITION HAVING ANTIMICROBIAL ACTIVITY<br/>[FR] MACROLIDES SUBSTITUES EN POSITION 3 POSSEDANT UNE ACTIVITE ANTIMICROBIENNE
申请人:GLAXO GROUP LTD
公开号:WO2004101584A1
公开(公告)日:2004-11-25
The present invention relates to 14- or 15-membered macrolides substituted at the 3-position of formula (I) and pharmaceutically acceptable derivatives thereof, to processes for their preparation and their use in therapy or prophylaxis of systemic or topical microbial infections in a human or animal body.
The present invention relates to 14- or 15-membered macrolides substituted at the 4″ position of formula (I)
and pharmaceutically acceptable derivatives thereof, to processes for their preparation and their use in therapy or prophylaxis of systemic or topical microbial infections in a human or animal body.